Close Menu

GnuBio

The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments. 

NEW YORK (GenomeWeb) — Bio-Rad reported after the close of the market on Tuesday a 5 percent increase in third quarter revenues including a 6 percent spike in sales for its Life Science segment.

This article was originally published May 12.

NEW YORK (GenomeWeb) — Bio-Rad this week reported a net sales increase of 3 percent in its Life Science segment in the first quarter versus the same period last year.

NEW YORK (GenomeWeb) — Bio-Rad said after the close of the market on Tuesday that its first quarter revenues increased 2 percent as its Life Science sales spiked 3 percent year over year.

Bio-Rad Laboratories said last week that it acquired next-generation sequencing technology firm GnuBio for an undisclosed price with the goal of commercializing a clinical NGS system.

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has purchased next-generation sequencing technology firm GnuBio for an undisclosed price in order to give it capabilities in the NGS space, especially for clinical applications, Bio-Rad said this week.

At the Consumer Genetics Conference last week in Boston, GnuBio unveiled its $50,000 desktop sequencer, which recently shipped to the first of the company's beta testers ahead of a wider commercial launch of the system expected next year.

Scientists from the University of California, San Francisco, and the California Institute for Quantitative Biosciences, or QB3, have published a study demonstrating how picoinjection can be used to precisely and efficiently add reagents to individual digital PCR reaction volumes

Personalis has launched services for genomic sequencing and interpretation, including its ACE Exome and ACE Genome sequencing services, which supplement standard exome and whole-genome sequencing with additional targeted sequencing to improve acc

Pages

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.